| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
,
*
Center for Cell and Gene Therapy and Departments of
Pediatrics,
Surgery, and
Molecular Virology and Microbiology, Baylor College of Medicine, Houston, TX 77030
Adoptive immunotherapy with EBV-specific CTL (EBV-CTL) effectively prevents and treats EBV-driven lymphoproliferation in immunocompromised hosts. EBV-seronegative solid organ transplant recipients are at high risk of EBV-driven lymphoproliferation because they lack EBV-specific memory T cells. For the same reason, standard techniques for generating EBV-CTL in vitro from EBV-naive individuals are unsuccessful. To overcome this problem, we compared several methods of expanding EBV-CTL from seronegative adults and children. First, the standard protocol, using EBV-transformed lymphoblastoid B cell lines (LCL) as the source of APC, was compared with protocols using EBV-Ag-loaded dendritic cells as APC. Surprisingly, the standard protocol effectively generated CTL from all seronegative adults. The additional finding of EBV-DNA in the peripheral blood of three of these four adults suggested that some individuals may develop cellular, but not humoral, immune responses to EBV. By contrast, LCL failed to reactivate EBV-CTL from any of the six EBV-seronegative children. EBV-Ag-loaded dendritic cells could expand EBV-CTL, but only in a minority of children. However, the selective expansion of CD25-expressing T cells, 9–11 days after activation with LCL alone, proved to be a simple and reliable method for generating EBV-CTL from all seronegative children. The majority of these CTL were CD4+ (71 ± 26%) and demonstrated HLA class II-restricted, EBV-specific killing. Our results suggest that a negative EBV serology does not accurately identify EBV-negative individuals. In addition, our method for selecting EBV-specific CTL from naive individuals by precursor cell enrichment may be applicable to the immunotherapy of cancer patients with a low frequency of tumor- or virus-specific CTL.
This article has been cited by other articles:
|
|
 |
|
  H. M. Long, J. Zuo, A. M. Leese, N. H. Gudgeon, H. Jia, G. S. Taylor, and A. B. Rickinson CD4+ T-cell clones recognizing human lymphoma-associated antigens: generation by in vitro stimulation with autologous Epstein-Barr virus-transformed B cells Blood, July 23, 2009; 114(4): 807 - 815. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Quintarelli, G. Dotti, B. De Angelis, V. Hoyos, M. Mims, L. Luciano, H. E. Heslop, C. M. Rooney, F. Pane, and B. Savoldo Cytotoxic T lymphocytes directed to the preferentially expressed antigen of melanoma (PRAME) target chronic myeloid leukemia Blood, September 1, 2008; 112(5): 1876 - 1885. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Liu, H.-E. Claesson, Y. Mahshid, G. Klein, and E. Klein Leukotriene B4 activates T cells that inhibit B-cell proliferation in EBV-infected cord blood-derived mononuclear cell cultures Blood, March 1, 2008; 111(5): 2693 - 2703. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Tanijiri, T. Shimizu, K. Uehira, T. Yokoi, H. Amuro, H. Sugimoto, Y. Torii, K. Tajima, T. Ito, R. Amakawa, et al. Hodgkin's Reed-Sternberg cell line (KM-H2) promotes a bidirectional differentiation of CD4+CD25+Foxp3+ T cells and CD4+ cytotoxic T lymphocytes from CD4+ naive T cells J. Leukoc. Biol., September 1, 2007; 82(3): 576 - 584. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W. H. Lim, S. Kireta, G. R. Russ, and P. T. H. Coates Human plasmacytoid dendritic cells regulate immune responses to Epstein-Barr virus (EBV) infection and delay EBV-related mortality in humanized NOD-SCID mice Blood, February 1, 2007; 109(3): 1043 - 1050. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
O. Beck, M. S. Topp, U. Koehl, E. Roilides, M. Simitsopoulou, M. Hanisch, J. Sarfati, J. P. Latge, T. Klingebiel, H. Einsele, et al. Generation of highly purified and functionally active human TH1 cells against Aspergillus fumigatus Blood, March 15, 2006; 107(6): 2562 - 2569. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. H. Gudgeon, G. S. Taylor, H. M. Long, T. A. Haigh, and A. B. Rickinson Regression of Epstein-Barr Virus-Induced B-Cell Transformation In Vitro Involves Virus-Specific CD8+ T Cells as the Principal Effectors and a Novel CD4+ T-Cell Reactivity J. Virol., May 1, 2005; 79(9): 5477 - 5488. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Liu, J. L. Arbiser, A. Holmgren, G. Klein, and E. Klein PSK and Trx80 inhibit B-cell growth in EBV-infected cord blood mononuclear cells through T cells activated by the monocyte products IL-15 and IL-12 Blood, February 15, 2005; 105(4): 1606 - 1613. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A.-L. Ponsonby, I. van der Mei, T. Dwyer, L. Blizzard, B. Taylor, A. Kemp, R. Simmons, and T. Kilpatrick Exposure to Infant Siblings During Early Life and Risk of Multiple Sclerosis JAMA, January 26, 2005; 293(4): 463 - 469. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. E. Davis, M. A. Sherritt, M. Bharadwaj, L. E. Morrison, S. L. Elliott, L. M. Kear, J. Maddicks-Law, T. Kotsimbos, D. Gill, M. Malouf, et al. Determining virological, serological and immunological parameters of EBV infection in the development of PTLD Int. Immunol., July 1, 2004; 16(7): 983 - 989. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Li Pira, L. Bottone, F. Ivaldi, R. Pelizzoli, F. Del Galdo, L. Lozzi, L. Bracci, A. Loregian, G. Palu, R. De Palma, et al. Identification of new Th peptides from the cytomegalovirus protein pp65 to design a peptide library for generation of CD4 T cell lines for cellular immunoreconstitution Int. Immunol., May 1, 2004; 16(5): 635 - 642. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 I. Kang, T. Quan, H. Nolasco, S.-H. Park, M. S. Hong, J. Crouch, E. G. Pamer, J. G. Howe, and J. Craft Defective Control of Latent Epstein-Barr Virus Infection in Systemic Lupus Erythematosus J. Immunol., January 15, 2004; 172(2): 1287 - 1294. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Bickham, K. Goodman, C. Paludan, S. Nikiforow, M. L. Tsang, R. M. Steinman, and C. Munz Dendritic Cells Initiate Immune Control of Epstein-Barr Virus Transformation of B Lymphocytes In Vitro J. Exp. Med., December 1, 2003; 198(11): 1653 - 1663. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Nikiforow, K. Bottomly, G. Miller, and C. Munz Cytolytic CD4+-T-Cell Clones Reactive to EBNA1 Inhibit Epstein-Barr Virus-Induced B-Cell Proliferation J. Virol., November 15, 2003; 77(22): 12088 - 12104. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. J. Amrolia, G. Muccioli-Casadei, E. Yvon, H. Huls, U. Sili, E. D. Wieder, C. Bollard, J. Michalek, V. Ghetie, H. E. Heslop, et al. Selective depletion of donor alloreactive T cells without loss of antiviral or antileukemic responses Blood, September 15, 2003; 102(6): 2292 - 2299. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. M. Posavad, A. Wald, N. Hosken, M. L. Huang, D. M. Koelle, R. L. Ashley, and L. Corey T Cell Immunity to Herpes Simplex Viruses in Seronegative Subjects: Silent Infection or Acquired Immunity? J. Immunol., April 15, 2003; 170(8): 4380 - 4388. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. C.M. Straathof, C. M. Bollard, C. M. Rooney, and H. E. Heslop Immunotherapy for Epstein-Barr Virus-Associated Cancers in Children Oncologist, February 1, 2003; 8(1): 83 - 98. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. Savoldo, M. H. Huls, Z. Liu, T. Okamura, H.-D. Volk, P. Reinke, R. Sabat, N. Babel, J. F. Jones, J. Webster-Cyriaque, et al. Autologous Epstein-Barr virus (EBV)-specific cytotoxic T cells for the treatment of persistent active EBV infection Blood, December 1, 2002; 100(12): 4059 - 4066. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Omiya, C. Buteau, H. Kobayashi, C. V. Paya, and E. Celis Inhibition of EBV-Induced Lymphoproliferation by CD4+ T Cells Specific for an MHC Class II Promiscuous Epitope J. Immunol., August 15, 2002; 169(4): 2172 - 2179. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
